Vilon
KE Dipeptide · Thymus Immune Bioregulator
Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells. Research shows Vilon increases mean lifespan by 20-40% in animal studies and suppresses tumor development.
Overview
Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells. Research shows Vilon increases mean lifespan by 20-40% in animal studies and suppresses tumor development.
Vilon works through epigenetic modulation, restoring chromatin structure and gene expression in immune cells. It stimulates thymocyte proliferation, activates T-helper cells, and increases the proliferative index in thymus tissue (from 26% to 37% in studies). The peptide modulates tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and helps rejuvenate aged immune systems by restoring proper gene expression patterns.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Stimulates thymocyte proliferation and enlarges thymic lobules.
Activates T-helper cells and improves immune response.
Restores chromatin structure and gene expression in aged lymphocytes.
Long-term treatment increased mean lifespan 20-40% in rodent studies.
Suppresses development of spontaneous and induced tumors.
Promotes recovery in tissues exposed to radiation damage.
Restores brush border membrane enzyme levels in aged animals.
Enhances intestinal barrier function in aged rats.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Dipeptide bioregulator
- Chain length
- 2 residues
- Molecular weight
- 275 Da
- Typical dose
- 10-20 mg per day (oral capsules) or 10 mg (injectable)
- Frequency
- Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
- Cycle length
- 10-20 day cycle (typical 10 days in research)
- Storage
- Oral capsules: room temperature; Lyophilized powder/reconstituted: 2-8°C refrigerated
Molecular data
- Type
- Dipeptide bioregulator
- Molecular weight
- 275 Da
- Chain length
- 2 residues
KEDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Research protocol | IM or SubQ | 10 mg | Daily for 10 days |
Interactions
Both target thymus/immune system; complementary mechanisms.
Often combined in comprehensive anti-aging Khavinson protocols.
Both have immunoprotecting properties; different mechanisms.
Related immune peptides; can be used in comprehensive protocols.
Quality checklist
- ✓White powder or capsules
- ✓Clear solution if reconstituted
- ✓Proper packaging and labeling
- !Unknown source or purity
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
What to expect
Safety
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual immune symptoms
- Active autoimmune flares (consult physician)
- Known hypersensitivity
- Pregnancy or breastfeeding
FAQ
How significant is the 20-40% lifespan extension from Vilon - is it proven in humans?
Animal studies showed 20-40% mean lifespan increases with long-term Vilon treatment plus tumor suppression. These are compelling preclinical findings but haven't been replicated in human longevity trials - lifespan extension is theorized based on mechanisms and animal models rather than clinical proof. Effects in humans are likely more modest.
Can Vilon be used continuously or must it follow the 10-20 day cycling protocol?
Vilon follows Khavinson bioregulator cycling: 10-20 days on, then off, repeated 2-3 times yearly. Cycling allows the body's natural feedback mechanisms to maintain homeostasis and prevents tolerance. Continuous use isn't recommended and may blunt epigenetic effects through feedback inhibition.
Does Vilon improve intestinal health and can it help with digestive issues?
Yes, Vilon restores brush border membrane enzyme levels and enhances intestinal barrier function in aged animals. This suggests potential benefits for age-related digestive decline and GI barrier integrity. However, direct clinical data for specific digestive conditions is limited - benefits are inferred from mechanisms.
Is Vilon the shortest bioregulator peptide and does size matter for absorption?
Yes, Vilon is the shortest Khavinson peptide at just 2 amino acids, giving it excellent oral absorption. The dipeptide size allows convenient capsule administration with good GI bioavailability - making it more practical than longer peptide bioregulators requiring injection.